Search
Now showing items 271-280 of 512
ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma.
(AMER ASSOC CANCER RESEARCH, 2019-10-15)
Tumor cells proliferate rapidly and thus are frequently subjected to replication stress and the risk of incomplete duplication of the genome. Fragile sites are replicated late, making them more vulnerable to damage when ...
Pazopanib in advanced soft tissue sarcomas.
(NATURE PUBLISHING GROUP, 2019-05-17)
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
(NATURE PORTFOLIO, 2019-05-21)
Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ...
Beyond DNA repair: the novel immunological potential of PARP inhibitors.
(TAYLOR & FRANCIS INC, 2019-01-01)
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...
FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas.
(Frontiers Media SA, 2019-03-13)
The heterogeneous and invasive nature of pediatric gliomas poses significant treatment challenges, highlighting the importance of identifying novel chemotherapeutic targets. Recently, recurrent Fibroblast growth factor ...
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses.
(NATURE PUBLISHING GROUP, 2019-08-02)
Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ...
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
(TAYLOR & FRANCIS LTD, 2019-10-30)
Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ...
Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
(Springer Science and Business Media LLC, 2017-05-01)
The origin of cancers is associated with etiology as well as therapeutics. Several studies reveal that malignancies in children can originate in utero. However, a diagnostic approach to distinguish between cancers initiated ...
Origins of STIL-TAL1 fusion genes in children who later developed paediatric T-cell acute lymphoblastic leukaemia: An investigation of neonatal blood spots.
(Wiley, 2018-11-01)
SCL/TAL1 interrupting locus (STIL)-T-cell acute leukaemia (TAL1) fusion genes are present in approximately 11-27% of children with paediatric T-cell acute lymphoblastic leukaemia (T-ALL), but the developmental timing of ...